<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>To assess the contribution of inherited <z:e sem="disease" ids="C0272375" disease_type="Disease or Syndrome" abbrv="">antithrombin deficiency</z:e> to mortality, we investigated the causes of <z:hpo ids='HP_0011420'>death</z:hpo> in 14 families with inherited <z:e sem="disease" ids="C0272375" disease_type="Disease or Syndrome" abbrv="">antithrombin deficiency</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Between 1830 and 1994, 86 of 266 family members who had a probability of 0.5 or more for heterozygosity died </plain></SENT>
<SENT sid="2" pm="."><plain>The causes of <z:hpo ids='HP_0011420'>death</z:hpo> were obtained for 58 of 66 <z:hpo ids='HP_0011420'>deaths</z:hpo> occurring between 1940 and 1994 </plain></SENT>
<SENT sid="3" pm="."><plain>Standardized mortality ratios (SMR) were calculated using mortality rates from the general population adjusted for age, sex and calendar period </plain></SENT>
<SENT sid="4" pm="."><plain>The overall SMR was 0.90 from 1830 to 1994 (95% C.I </plain></SENT>
<SENT sid="5" pm="."><plain>0.72-1.11) </plain></SENT>
<SENT sid="6" pm="."><plain>From 1940 until 1994 44 men and 22 women died (SMR = 1.09, 95% C.I </plain></SENT>
<SENT sid="7" pm="."><plain>0.84-1.39; SMR men = 1.20, 95% C.I </plain></SENT>
<SENT sid="8" pm="."><plain>0.87-1.61; SMR women = 0.92, 95% C.I </plain></SENT>
<SENT sid="9" pm="."><plain>0.58-1.39) </plain></SENT>
<SENT sid="10" pm="."><plain>No excess mortality compared to the general population was found for <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> (14 <z:hpo ids='HP_0011420'>deaths</z:hpo>) or circulatory diseases (28 <z:hpo ids='HP_0011420'>deaths</z:hpo>) </plain></SENT>
<SENT sid="11" pm="."><plain>A slightly increased mortality caused by <z:e sem="disease" ids="C0035204" disease_type="Disease or Syndrome" abbrv="">respiratory diseases</z:e> (7 <z:hpo ids='HP_0011420'>deaths</z:hpo>, SMR = 1.68, 95% C.I </plain></SENT>
<SENT sid="12" pm="."><plain>0.68-3.47) seemed due to <z:hpo ids='HP_0002090'>pneumonia</z:hpo> (4 <z:hpo ids='HP_0011420'>deaths</z:hpo>, SMR = 2.86, 95% C.I </plain></SENT>
<SENT sid="13" pm="."><plain>0.78-7.32) </plain></SENT>
<SENT sid="14" pm="."><plain>Venous thromboembolic complications were listed once in association with a risk situation, and one other <z:hpo ids='HP_0011420'>death</z:hpo> could be attributed to fatal <z:hpo ids='HP_0002204'>pulmonary embolism</z:hpo> </plain></SENT>
<SENT sid="15" pm="."><plain><z:hpo ids='HP_0001342'>Cerebral hemorrhages</z:hpo> were listed three times </plain></SENT>
<SENT sid="16" pm="."><plain>It could not be verified whether these <z:mp ids='MP_0001914'>hemorrhages</z:mp> were related to <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> therapy; the frequency was slightly higher than the expected population figure (SMR = 1.49, 95% C.I </plain></SENT>
<SENT sid="17" pm="."><plain>0.31-4.36) </plain></SENT>
<SENT sid="18" pm="."><plain>The mean age of <z:hpo ids='HP_0011420'>death</z:hpo> for <z:hpo ids='HP_0000001'>all</z:hpo> causes was 64 years; the two fatal thromboembolic episodes occurred at age 20 and 30 years </plain></SENT>
<SENT sid="19" pm="."><plain>The data show that <z:e sem="disease" ids="C0272375" disease_type="Disease or Syndrome" abbrv="">antithrombin deficiency</z:e> is associated with a <z:mpath ids='MPATH_458'>normal</z:mpath> survival and a low risk of fatal <z:hpo ids='HP_0001907'>thromboembolic events</z:hpo> </plain></SENT>
<SENT sid="20" pm="."><plain>The use of long-term <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> treatment in asymptomatic individuals should be considered carefully in view of the greater risk of fatal <z:mp ids='MP_0001914'>bleeding</z:mp> associated with long-term <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> prophylaxis </plain></SENT>
</text></document>